Expression of NF‐κB‐related proteins and their modulation during TNF‐α‐provoked apoptosis in prostate cancer cells
- 25 April 2011
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 72 (1) , 40-50
Abstract
BACKGROUND: The involvement of TNF‐α in cancer development is controversial, since this cytokine was reported to act either as tumor promoter or suppressor. TNF‐α may activate signaling pathways critical for life/death decisions, such as mitogen‐activated protein kinases (MAPKs) and the anti‐apoptotic NF‐κB pathway. In this work, we investigate the activation status of NF‐κB‐related proteins in human prostate cancerous versus normal epithelium, and the alterations in the NF‐κB pathway in relation to cell death in TNF‐α‐treated LNCaP (androgen‐independent cells) and PC3 (androgen‐independent) prostate cancer cell lines.METHODS: The expression of phospho‐p38‐MAPK, phospho‐IKK‐α/β and phospho‐IκB‐α, total IκB‐α, and p65‐ and p50‐NF‐κB, were analyzed by immunohistochemistry in cancerous and normal prostate samples. The toxicity of TNF‐α in LNCaP and PC3 cells, with or without kinase and NF‐κB inhibitors, was assessed by changes on viability (MTT assay) and apoptosis (loss of DNA, annexin‐V binding, and caspase cleavage/activation). Expression of NF‐κB‐related proteins in these cell lines was measured by Western blot.RESULTS: Phospho‐IκB‐α, phospho‐IKK‐α/β and phospho‐p38 levels, cytoplasmic p50 to IκB‐α ratio, and nuclear p50 and p65, levels, were increased in cancerous epithelium, suggesting activation of the NF‐κB pathway in prostatic malignance. TNF‐α caused apoptosis with higher efficacy in LNCaP cells, and this response was potentiated by p38‐MAPK inhibitor (LNCaP cells) and IKK‐β inhibitor (both cell lines). However, the protective action of IKK‐β was mediated by NF‐κB only in LNCaP cells.CONCLUSIONS: IKK‐β mediates both NF‐κB‐dependent and ‐independent anti‐apoptotic functions in prostate cancerous epithelium. IKK‐β and p38‐MAPK may represent useful therapeutic targets against prostate cancer. Prostate 72:40–50, 2012.Keywords
Funding Information
- Consejo Superior de Investigaciones Científicas (201020E037)
- Ministerio de Educación y Ciencia, Spain (SAF2007-64721, SAF2007-61928)
- (Plan Nacional de Investigación Científica; Desarrollo e Innovación Tecnológica; Dirección General de Investigación)
- Mutua Madrileña de Automóviles Foundation (AP76182010)
This publication has 25 references indexed in Scilit:
- Role of IAPs in prostate cancer progression: immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostateBMC Cancer, 2010
- Inhibiting TNF-mediated signaling: a novel therapeutic paradigm for androgen independent prostate cancerApoptosis, 2009
- Tumour necrosis factor and cancerNature Reviews Cancer, 2009
- Pharmacologic inhibitors of extracellular signal‐regulated kinase (ERKs) and c‐Jun NH2‐terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia Cells to arsenic trioxide‐induced apoptosisJournal of Cellular Physiology, 2006
- Nuclear factor-κB in cancer development and progressionNature, 2006
- Convergent Actions of IκB Kinase β and Protein Kinase Cδ Modulate mRNA Stability through Phosphorylation of 14-3-3β Complexed with TristetraprolinMolecular and Cellular Biology, 2005
- IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3aCell, 2004
- p38 MAPK-induced Nuclear Factor-κB Activity Is Required for Skeletal Muscle Differentiation: Role of Interleukin-6Molecular Biology of the Cell, 2004
- CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV ResponseMolecular Cell, 2003
- IMMUNOEXPRESSION OF TUMOUR NECROSIS FACTOR-α AND ITS RECEPTORS 1 AND 2 CORRELATES WITH PROLIFERATION/APOPTOSIS EQUILIBRIUM IN NORMAL, HYPERPLASIC AND CARCINOMATOUS HUMAN PROSTATECytokine, 2000